一分钟看懂
这是一项关于小细胞肺癌的III 期研究，登记的药物或干预包括YL201；topotecan hydrochloride for injection，当前状态为研究进行中，已停止招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
YL201；topotecan hydrochloride for injection · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- 1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures.
- 2. Aged ≥18 and ≤75 years, male or female.
- 3. ECOG PS 0 or 1.
- 4. Life expectancy ≥ 3 months.
- 5. Histologically or cytologically confirmed SCLC. Subjects with combined SCLC or any transformed SCLC are not eligible.
- 6. Has limited-stage or extensive-stage disease at study entry, with progression on or after first-line platinum-based therapy (at least 2 cycles).
- 7. At least one measurable lesion according to RECIST version 1.1.
- 8. Subjects are willing to provide tumor tissue (freshly obtained or archived) for detection of B7-H3 expression.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06612151；登记信息更新于 2026-09-15。